Last reviewed · How we verify
Physician based insulin regime
The physician-based insulin regime, marketed by Shanghai Zhongshan Hospital, holds a position in the diabetes management market with a key composition patent expiring in 2028. A key strength of this regime is its reliance on physician guidance, which may enhance patient adherence and outcomes. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | Physician based insulin regime |
|---|---|
| Also known as | iGMS + routine insulin treatment regime |
| Sponsor | Shanghai Zhongshan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Efficacy and Safety of iNCDSS in Type 2 Diabetes Mellitus Patients (NA)
- AI-Assisted Insulin Titration System on Inpatients Glucose Control (NA)
- Artificial Intelligence Assisted Insulin Titration System (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Physician based insulin regime CI brief — competitive landscape report
- Physician based insulin regime updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI